Biosensors Announces Appointment of New CEO - Jose Calle Gordo

Mr Jose Calle Gardo has led an illustrious career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Eli Lilly, and Guidant. He led the global team that developed and commercialized Xience a family of drug eluting stents (DES) and a market leader for the treatment of coronary artery disease with global sales of more than $1.6 billion while serving as Vice President and General Manager of Drug Eluting Stents Vascular Intervention at Guidant based in Santa Clara, CA, U.S.A.

As Vice President of Abbott Vascular based in Brussels, he later led the commercial introduction of Bioresorbable Vascular Scaffolds (ABSORB) and MitraClip, the world's first percutaneous mitral valve repair therapy. During his earlier years with Abbott, he spearheaded the integration of Guidant and Abbott Vascular Devices in 2006 and managed the international operations of Abbott Vascular outside the U.S. between 2011 and 2012.
http://infopub.sgx.com/Apps?A=COW_CorpAnnouncement_Content&B=AnnouncementToday&F=KD5PXZXH5ET6YSPZ